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Abstract: Due to their potent immunomodulatory anti-inflammatory properties, synthetic glucocorticoids
(GCs) are widely utilized in the treatment of chronic inflammatory disease. In this review, we examine
our current understanding of how chronic inflammation and commonly used therapeutic GCs interact
to regulate bone and muscle metabolism. Whilst both inflammation and therapeutic GCs directly
promote systemic osteoporosis and muscle wasting, the mechanisms whereby they achieve this are
distinct. Importantly, their interactions in vivo are greatly complicated secondary to the directly opposing
actions of GCs on a wide array of pro-inflammatory signalling pathways that underpin catabolic and
anti-anabolic metabolism. Several clinical studies have attempted to address the net effects of therapeutic
glucocorticoids on inflammatory bone loss and muscle wasting using a range of approaches. These have
yielded a wide array of results further complicated by the nature of inflammatory disease, underlying the
disease management and regimen of GC therapy. Here, we report the latest findings related to these
pathway interactions and explore the latest insights from murine models of disease aimed at modelling
these processes and delineating the contribution of pre-receptor steroid metabolism. Understanding these
processes remains paramount in the effective management of patients with chronic inflammatory disease.
Keywords: glucocorticoid; muscle wasting; osteoporosis
1. Glucocorticoids and Therapeutic Glucocorticoid Excess
Synthetic glucocorticoids (GCs), such as dexamethasone, prednisolone and hydrocortisone, are
widely utilized in the treatment of chronic inflammatory diseases such as chronic obstructive pulmonary
disease (COPD), inflammatory bowel disease (IBD) and rheumatoid arthritis (RA), with approximately
1% of the adult population in the U.K. and U.S. receiving this class of drugs. Their mechanisms of
action are diverse, with GCs suppressing a range of pro-inflammatory pathways including p38-mitogen
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activated protein kinases (p38-MAPK), nuclear factor kappa-light-chain-enhancer (NF-κB) and activator
protein (AP-1), in addition to inducing pro-resolving factors such as glucocorticoid induced leucine
zipper (GILZ) and annexin-1 [1–3]. These significantly reduce leukocyte infiltration at sites of
inflammation, suppress the production of pro-inflammatory cytokines and chemokines and support
resolution of inflammation and tissue remodelling [4,5]. Despite the potent immune-modulatory
anti-inflammatory actions of therapeutic GCs, their clinical application is limited due to severe systemic
side effects. These occur in up to 70% of patients and can include muscle wasting and GC induced
osteoporosis (GIO) [6–10]. The actions of GCs on bone and muscle metabolism are well established,
but themselves complicated in the backdrop of chronic inflammation by separate inflammatory driven
muscle wasting and bone loss. The inflammatory pathways that mediate bone and muscle loss
in chronic inflammation are in turn suppressed by the anti-inflammatory actions of GCs, further
complicating the prediction of their outcome on the musculoskeletal system. Understanding the
complex interactions between GC and inflammatory regulation of bone and muscle metabolism remains
paramount in the effective management of patients with chronic inflammatory disease. In this review,
we explore how inflammatory drivers and therapeutic GCs interact to regulate bone and muscle
metabolism and consider the role of local steroid metabolism in shaping these processes.
2. Glucocorticoid Signalling and Regulation of Inflammation
Lipophilic GCs readily diffuse across cell membranes, signalling through the cytoplasmic GC receptor
(GR) superfamily, encoded by the NR3C1 gene. Classically, GC signalling and GR transactivation occur
through ligand binding of the GRα homodimer. In its unbound state, GRα forms a multi-protein
complex with chaperone proteins such as heat shock proteins (HSPs), HSPp-70, HSP90 and FK506
binding protein 52 that block their nuclear localization signal (NLS) and prevent translocation to the
nucleus from the cytoplasm [11]. Upon GC binding, the GRα undergoes a conformational change,
allowing dissociation of chaperone proteins. Homo-dimerization and exposure of the NLS are required
for nuclear translocation of the ligand bound GR, where it can influence gene expression [12] (Figure 1).
This is an oversimplified view of GC signalling, as several studies utilizing the GRdim mouse (possessing
a mutation preventing GR dimerization) reveal that the anti-inflammatory properties of therapeutic GCs
are mediated by both homo-dimeric GRα complexes and monomeric GRα to facilitate transactivation
or transrepression of pro-inflammatory genes [5,13–16]. Whilst the mechanisms that underpin GR
signalling have been reviewed extensively elsewhere, several key pathways are prominent in mediating
the anti-inflammatory actions of GCs [17]. These include the direct GRα homodimer transactivation
of anti-inflammatory genes such as secretory leukocyte protease inhibitor (SLPI), MAKP-1, GILZ and
tristetraprolin (TTP), which suppress the NF-kB and p38-MAPK inflammatory pathways, in addition to
the inhibition of pro-inflammatory transcription factors via their tethering to the GC bound GR [18–21].
In particular, GCs act via the GR to suppress the NF-κB and p38-MAPK inflammatory pathways and AP-1
pro-inflammatory pathways, which regulate the transcription of various genes relating to inflammation
such as tumour necrosis factor-alpha (TNF-α) and interleukin-1 (IL-1β) and -6 [22]. Many of these
inflammatory pathways considered are direct contributors to the process of inflammatory bone and
muscle wasting and are themselves opposed by the actions of therapeutic GCs. This review will now
consider how inflammation and GCs influence bone and muscle metabolism, both in isolation and in
concert with one another.
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Figure 1. Overview of glucocorticoid (GC) signalling pathways. The majority of glucocorticoids (GCs) 
in the circulation are bound by corticosteroid-binding globulin (CBG), which prevents diffusion 
across the membrane. However, free GCs can readily enter the cell, where they bind to the GR in the 
cytoplasm. This induces a conformational change in the glucocorticoid receptor (GR), which causes 
the dissociation of chaperone molecules, such as heat shock proteins (HSPs), to expose the nuclear 
localisation signal (NLS) and allow translocation of the GC/GR complex to the nucleus. Here, the GR 
can either dimerise to transactivate anti-inflammatory genes or signal as a monomer to inhibit pro-
inflammatory transcription factors. Cortisol (CORT), nuclear factor of activated T-cells (NFAT), 
CCAAT-enhancer-binding proteins (or C/EBPs), nuclear factor kappa-light-chain-enhancer of 
activated B cells (NF-κB), p38 mitogen-activated protein kinases (p-38-MAPK), glucocorticoid 
induced leucine zipper (GILZ), secretory leukocyte protease inhibitor (SLPI), tristetraprolin (TTP), 
mitogen-activated protein kinase-1 (MKP-1), activator protein 1 (AP-1), signal transducer and 
activator of transcription 5 (STAT5), and response element (RE). 
3. Bone Metabolism 
Bone metabolism is a tightly regulated process that ensures homeostasis between bone 
resorption and bone formation. This process maintains a balance in calcium and phosphate mineral 
homeostasis, as well as allowing constant healthy remodelling to compensate for external loading 
stress and damage and requires the close interaction between osteocytes, bone lining cells, bone 
forming osteoblasts and bone resorbing osteoclasts [23]. Here, in quiescent bone, osteocytes produce 
factors such as transforming growth factor-β (TGF-β), sclerostin and dickkopf WNT signaling 
pathway inhibitor 1 (DKK-1), which inhibits osteoclast and osteoblast maturation and differentiation 
[24]. Signals such as bone matrix damage or immobilization result in osteocyte apoptosis, leading to 
a removal of the inhibitory signals and increases in factors that promote osteoclastogenesis, such as 
macrophage colony stimulating factor (M-CSF) and receptor activator of nuclear factor kappa-β 
ligand (RANKL) [25–27]. Together, these promote osteoclast differentiation from hematopoietic 
precursors and increase receptor activator of nuclear factor kappa-β (RANK) pathway activation, 
driving multinuclear polykaryon formation and the formation of mature osteoclasts that express 
osteoclast specific genes including tartrate-resistant acid phosphatase (TRAP) and cathepsin K [28–
Figure 1. Overview of glucocorticoid (GC) signalling pathways. The majority of glucocorticoids
(GCs) in the circulation are bound by corticosteroid-binding globulin (CBG), which prevents diffusion
across the membran . However, free GCs can re ly enter th cell, wh re they bind to t GR in the
cytoplasm. This induces a conformational change in the glucocorticoid receptor (GR), which causes
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zipper (GILZ), secretory leukocyte protease inhibitor (SLPI), tristetraprolin (TTP), mitogen-activated
protein kinase-1 (MKP-1), activator protein 1 (AP-1), signal transducer and activator of transcription 5
(STAT5), and response element (RE).
3. Bone M tabolism
Bone metabolism is a tightly regulated process that ensures homeostasis between bone resorption
and bone ati n. This process maintains a balance in calc um and phosphate mine al homeostasis,
as well as allowing constant healthy remodelling to compensate for external loading stress and damage
and requires the close interaction between osteocytes, bone lining cells, bone forming osteoblasts
and bone resorbing osteoclasts [23]. Here, in quiescent bone, osteocytes produce factors such as
transforming growth factor-β (TGF-β), sclerostin nd dickkopf WNT signaling pathway inhibitor 1
(DKK-1), which inhibits osteoclast and osteoblast maturation and differentiation [24]. Signals such
as bone matrix damage or immobilization result in osteocyte apoptosis, leading to a removal of the
inhibitory signals and increases in factors that promote osteoclastogenesis, such as macrophage colony
stimulating factor (M-CSF) and receptor activator of nuclear factor kappa-β ligand (RANKL) [25–27].
Together, these promote osteoclast differentiation from hematopoietic precursors and increase receptor
activator of nuclear factor kappa-β (RANK) pathway activation, driving multinuclear polykaryon
formation and the formation of mature osteoclasts that express osteoclast specific genes including
tartrate-resistant acid phosphatase (TRAP) and cathepsin K [28–30]. Mature osteoclasts form tight
integrin junctions on mineralized bone matrix, forming an acidified resorption compartment that
facilitates the degradation of the inorganic hydroxyapatite component of the bone [31,32]. The organic
component of bone can then be degraded by lysosomal enzymes, such as cathepsin K. In parallel to this
process, a reduction in factors that suppress osteoblast differentiation (such as sclerostin and DKK-1)
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and an increase in factors that induce osteoblast differentiation (such as WNT, TGFβ and insulin-like
growth factor 1 (IGF-1)) promote the formation of osteoblast pre-cursors from mesenchymal derived
progenitors [33–35]. This process is tightly regulated through the master transcriptional regulator
runt-related transcription factor 2 (RUNX2), mediating the expression of osteoblast specific genes
such as osteocalcin, osteopontin and bone sialoprotein [36,37]. As osteoblasts continue to mature,
RANKL levels (which maintain osteoclasts) decrease, whilst osteoprotegerin (OPG) (the dummy
receptor for RANKL that suppresses RANK signalling) increases. Together with increasing TGFβ
signalling, the decrease in RANK/RANKL signalling leads to reduced osteoclast differentiation, activity
and survival [38]. The transition toward the reversal phase is characterised by an increase in mature
osteoblasts at the vacated osteoclast lacunae site of bone resorption. One key cell type that appears to
facilitate this transition appears to be a unique cell population known as reversal cells, which cover
the eroded bone surface. Here, one study has revealed that the disruption of these cells results in a
loss of the initiation of bone resorption, highlighting their importance in this process [39]. Mature
osteoblasts then secrete factors required for osteoid formation including organic matrix rich in type 1
collagen, osteocalcin and bone sialoprotein (BSP) [40]. This is then mineralized via the deposition of
hydroxyapatite crystals, created by the flux of calcium and phosphate ions within vesicles that are
deposited as a mineralized nodule, in a process that has been shown to require the enzyme alkaline
phosphatase to release phosphate ions [41,42]. Ultimately, bone formation ceases as osteoblasts undergo
apoptosis or are incorporated into the osteocyte network.
4. Regulation of Bone Metabolism by Inflammation
In diseases such as RA, IBD and COPD, ongoing systemic inflammation results in inflammatory
osteoporosis, with localized destruction of bone at sites of inflammation in diseases such as RA [43–47].
Systemic bone loss is characterized by a general decrease in bone mineral density (BMD) at the femoral
neck, hip and spine in patients, resulting in increased fracture rates [47–50]. It is widely accepted that
this inflammatory bone loss results from an imbalance in the bone remodelling cycle, shifting towards
resorption and away from formation [51]. Studies exploring inflammatory bone loss are complicated by
immobility in patients and the impact of concurrent anti-inflammatory drugs that can influence bone
metabolism. However, significant insights have been derived from in vitro studies and clinical studies.
A prominent mechanism associated with a shift toward inflammatory bone loss is the interaction
of the activated immune system with bone resorbing osteoclasts. Here, changes in the inflammatory
cytokine profiles in patients with chronic inflammation result in increased levels of pro-osteoclastogenic
mediators and a decrease in anti-osteoclastogenic mediators. Many of the pro-osteoclastogenic
cytokines upregulated in chronic inflammation, including TNF-α, IL-1, IL-6, IL-8 and IL-17, mediate
their actions via an upregulation of RANKL on fibroblasts and osteoblasts, which in turn promotes
osteoclastic bone resorption [52–55]. In particular, combinations of cytokines including TNF-α, IL-1
and IL-6, act synergistically to increase RANKL in inflammation [56]. Activated Th17 and B cells also
upregulate RANKL expression promoting resorptive bone lesions in patients and in vitro in a RANKL
dependent manner [57–59]. A recent study identified a novel cytokine induced in response to TNF-α
in T cells, known as secreted osteoclastogenic factor of activated T cells (SOFAT), which has the ability
to cause osteoclastogenesis in a RANKL independent manner and may have implications in bone loss
induced by chronic inflammatory disease [60].
Of particular interest, TNF-α also has effects on the bone forming ability of osteoblasts in
inflammation. TNF-α treatment of osteoblasts’ precursors inhibits their differentiation by suppressing
the DNA binding ability of RUNX2, leading to inhibition of alkaline phosphatase expression and matrix
deposition [61]. The pro-apoptotic properties of TNF-α on osteoblasts has also been observed [62].
Similarly, IL-6 treatment of osteoblasts leads to reductions in alkaline phosphatase activity and in the
expression of RUNX2 and osteocalcin, with mineralisation dramatically reduced in a dose dependent
manner [63]. The prominent role of the inflammatory activation of osteoclastogenesis was derived
from murine models using the TNF-tg mouse of chronic polyarthritis and inflammatory bone loss.
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Here, blockade of both the TNF-α and the RANKL/RANK signalling pathways using anti-TNF therapy
in combination with anti-osteoclastic (OPG) was able to prevent inflammatory bone erosions [64].
Bone repair was then augmented through the addition of the pro-osteoblastic hormone parathyroid
hormone (PTH). These results highlight the importance of bot inflammatory activation of osteoclasts
and suppression of osteoblasts in mediating systemic and localized bone loss in chronic inflammation.
Consequently, these results indicate that repair of bone erosions requires a therapy that simultaneously
controls inflammation while also impacting both osteoclastic bone resorption and osteoblastic bone
formation to shift the balance in bone homeostasis and promote normal repair and recovery of bone.
5. Effects of Glucocorticoids on Bone Metabolism
Whilst GCs are widely used in the treatment of chronic inflammation, they are themselves
associated with an increased risk of fractures and osteoporosis at therapeutic doses resulting in GIO.
GIO is the most common form of secondary osteoporosis with risk of fracture increasing dramatically
within three to six months of starting GC therapy [65]. Interestingly, these changes are reversed
rapidly upon cessation of GCs, indicating a rapid and acute nature of action at the cellular level.
The mechanism that underpins this appears to be primarily mediated by a substantial inhibition of
osteoblastic bone formation [66]. Under physiological conditions, GCs promote osteoblast maturation.
However, at higher therapeutic doses, GCs downregulate WNT agonists and upregulate WNT
inhibitors, which induce apoptosis and suppress osteoblast differentiating [67–69]. In one clinical
study examining children receiving exogenous glucocorticoids, serum levels of the WNT signalling
inhibitor DKK-1 were shown to be significantly elevated, suggesting it may play a key role in reduced
bone formation in GIO [70]. In studies using transgenic mice with osteoblast targeted disruption of
glucocorticoid signalling, GC signalling via the GR was shown to mediate reduced bone formation
through the suppression of osteoblast differentiation via the WNT pathway and through inducing
osteoblast apoptosis, with animals with GR signaling disruption being protected from GC induced
bone loss [67,71].
The impact of GCs on osteoclasts is less clear. Studies have reported that GC treatment results in a
decrease in osteoclast number, but an increase in osteoclast longevity, potentially mediated via a GC
induced increase in M-CSF production [66,72,73]. In addition, studies have shown conflicting results
on the expression of osteoclastic genes in response to GCs. One study showed that dexamethasone
treatment of murine calvarial bones resulted in increased mRNA levels of Rank and Rankl, leading to
increased markers of osteoclast activation [74]. Other studies showed that OPG levels are suppressed
or reported no change at all in RANKL and OPG levels [72,75,76]. Some insight comes from one
study in children receiving exogenous GCs, where serum levels of RANKL were elevated and OPG
suppressed [77]. In these patients, spontaneous osteoclastogenesis in vitro was apparent in monocytic
cell precursors. Certainly, one study utilizing a murine model of therapeutic GC delivery revealed that
the targeting of osteoclasts using bisphosphonates was an effective strategy to prevent both cortical
and trabecular bone loss [78]. There is some evidence to indicate that the responsiveness of osteoclasts
to GCs is highly dependent on the stage of cell differentiation, but these findings require further
investigation [79]. The variation in GC dose, the method of administration and the models employed
may explain the variation in the results reported to date, whilst their interactions with inflammatory
mediators in patients with chronic inflammation should also be taken into account when investigating
their bone related effects.
6. Glucocorticoids, Inflammation and Bone Homeostasis
Glucocorticoids directly oppose a wide array of the pathways that drive inflammatory bone loss.
Amongst these, their suppression of pro-inflammatory factors such as RANKL, TNF-α and IL-6 appears
to be prominent in mediating their bone sparing effects in chronic inflammatory joint destruction,
through the direct suppression of osteoclastogenesis and osteoclast activation [80] (Figure 2). In contrast,
their potent suppression of anabolic bone formation by osteoblasts may synergize with the deleterious
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actions of inflammation on osteoblasts. Consequently, the net balance of GCs on bone metabolism
in the context of chronic inflammation is less clear. Several clinical studies shed light on the balance
between beneficial and detrimental actions of GCs on bone metabolism in chronic inflammation. These
include a study reporting no differences in BMD loss in RA patients receiving therapeutic GCs in
combination with traditional disease modifying anti-rheumatic drugs (DMARDS), relative to a matched
control cohort [81]. Of particular interest were studies exploring whether GCs at lower therapeutic
doses might promote positive anti-inflammatory actions without eliciting detrimental bone loss. These
studies reported that low dose GC therapy in RA did not increase the risk of generalized osteoporosis
at the spine and hip [82,83]. Another study found that patients receiving GCs in combination with
anti-TNF therapy had a 2.5% increase in BMD at the femoral neck compared to a 0.7% decrease
in BMD in those using anti-TNF alone, suggesting that GCs may increase bone metabolism in this
context [84]. In contrast, two further studies found that GCs’ use was associated with decreased BMD
in RA patients [43,85]. Similarly, in juvenile chronic arthritis (JCA), two studies found that GC treated
patients had significantly less trabecular bone and higher risk of vertebral collapse than a matched
control cohort [86,87]. These studies found strong links with the dose of steroid applied, but were
further complicated by the application of GCs in the developing skeleton of younger patients, who
may be more vulnerable to the anti-anabolic actions of GCs than adults. The conflicting nature of these
results may stem from a variety of issues, including differences in disease pathophysiology, disease
activity, duration and variations in the delivery and dose of GC therapy. In addition, concomitant use
of alternative therapies such as anti-TNF treatments causes further complications, making it difficult to
dissect the contribution of GCs to changes in bone metabolism in chronic inflammatory disease.
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Figure 2. Schematic representation of the effects of i fla matio and glucocorticoids (GCs) on bone
remodelling. During inflammation, elevated levels of pro-inflammatory cytokines, such as TNF-α and
IL-6, inhibit the differentiation of bone forming osteoblasts from their precursors. These cytokines, along
with other pro-inflammatory mediat rs including IL-1, IL-17 and IL-8, also upregulate the expression
of receptor activat r of nuclear factor kappa-B ligand (RANKL), which binds to receptor activator of
nuclear factor kappa-B (RANK) on pre-osteoclasts and triggers their differentiation into mature bone
resorbing osteoclasts. Overall, bone formation is decreased while bone resorption is increased, leading
to a net loss of bone. Although GCs suppress inflammation via suppression of pro-inflammatory factors
and induction of anti-inflammatory mediators, they can also independently drive bone loss by inhibiting
differentiation and inducing apoptosis of osteoblasts whilst increasing osteoclast differentiation by
stimulating expression of RANKL and decreasing its decoy receptor osteoprotegerin (OPG). Osteoblasts
(OBs), p38 mitogen-activated protein kinases (p-38-MAPK), glucocorticoid-induced leucine zipper
(GILZ), secretory leukocyte protease inhibitor (SLPI), tristetraprolin (TTP), mitogen-activated protein
kinase-1 (MKP-1), activator protein 1 (AP-1), OC (osteoclast), canonical WNT signalling (WNT), and
nuclear factor kappa-light-chain-enhancer of activated B cells (NF-κB).
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7. Muscle Mass Related Metabolism
Similar to bone, muscle metabolism is tightly regulated to ensure a balance between anabolic and
catabolic processes governing muscle mass. Its regulation is critical not only to facilitate mechanical
locomotion, but also as a key site for whole body energy metabolism and homeostasis [88]. Several
critical anabolic and catabolic signalling pathways determine muscle protein synthesis, muscle
proteolysis and myogenesis as cellular processes in control of muscle mass.
IGF-1 has been identified as a critical factor mediating the regulation of anabolic and catabolic
muscle homeostasis in adult myofibers. Produced primarily in the liver, its binding to the IGF-1
receptor (IGF1R) in skeletal muscle allows recruitment of the insulin receptor substrate 1 (IRS-1) and
activation of phosphatidylinositol-3-kinase (PI3K) and phosphorylation of protein kinase B (nnown
as AKT), [89,90]. Together, these result in the activation of the mammalian target of rapamycin
(mTOR) signalling pathway, which results in suppression of proteolysis and activation of muscle
protein synthesis. mTOR activation suppresses proteolytic, forkhead box class O family member
proteins (FOXOs) and glycogen synthase kinase-3 beta (GSK-3β) pathways [91,92]. The activation of
mTOR signalling promotes muscle protein synthesis through the downstream phosphorylation and
inactivation of eIF4E-binding protein 1 (4E-BP1) and activation of the ribosomal protein S6 kinase
beta-1 (p70S6K) [93–95]. When active, 4E-BP1 operates by suppressing the eukaryotic translation
initiation factors (elF), which are a central rate limiting step in the regulation of protein synthesis in
muscle. Here, eIF4F (a complex of initiation factors, eIF4e, eIF4G and eIF4A), promotes the translation
of mRNA coding for muscle proteins by facilitating the cap dependent binding of messenger RNA
to the 40S ribosomal subunit [96]. The repressor protein 4E-BP1 is a powerful negative regulator
of eIF4F mediated protein translation, whilst its phosphorylation causes its dissociation from eIF4E
and enables mRNA translation of anabolic muscle proteins. A second key stage in the regulation of
anabolic protein metabolism in muscle occurs through the regulation of phosphorylated p70S6K by
mTOR, which facilitates ribosomal biogenesis and translation capacity required for muscle protein
anabolism [97]. An additional modulator of skeletal muscle mass downstream of the IGF-1/AKT
pathway is GSK-3β. This protein kinase is a negative regulator of the translation initiation factor eIF2B
and is phosphorylated and inactivated by AKT, allowing initiation of mRNA translation [98–100].
Together, the activation of these pathways by IGF-1 or insulin promote protein synthesis in muscle,
favouring increased muscle mass.
The regulation of muscle catabolism shares many of these pathways and involves their inverse
activation state. Proteolysis of skeletal muscle proteins through their targeted degradation by the
ubiquitin-proteasome system (UPS) and autophagy pathways is under stringent control of the PI3K/AKT
and mTOR signalling pathways [101]. Here, a reduction in anabolic factors such as IGF-1 or an increase
in negative regulators such as myostatin, TGFβ or FGF results in a decrease of the PI3K/AKT and
mTOR signalling. As AKT and mTOR kinase activity is responsible for inhibitory phosphorylation
of the FOXOs, including FOXO1, FOXO3 and FOXO4 [102,103], the lack thereof allows their nuclear
translocation. FOXO transcription factors bind to promoter and enhancer regions of target genes such as
the E3 ligases, Atrogin-1 and muscle RING-Finger protein-1 (MURF-1) and the autophagy-related genes
LC3 and Bnip3 [104–107]. In addition to FOXO, increased GSK-3β secondary to reduced IGF-1/AKT
signalling has also been implicated in upregulating Atrogin-1 and MURF-1 [108].
The E3 ligases are the largest family of ubiquitination factors targeting muscle proteins for
degradation by the UPS [109,110] and can be highly upregulated in catabolic conditions. These include
the muscle specific F-box protein Atrogin-1 encoded by the FBXO32 gene and MURF-1 encoded by
the TRIM63 gene [111,112]. Their expression is elevated in a plethora of skeletal muscle atrophy
models, including immobilisation, denervation, cancer, starvation and diabetes [111–113]. Atrogin-1
has been shown to ubiquitinate desmin and vimentin, muscle proteins essential to sarcomere Z-disk
architecture [114]. In addition, Atrogin-1 stimulates the degradation of transcription factor EIF3F,
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leading to impaired muscle protein synthesis [115]. This E3 ligase has also been shown to play a
pivotal role in repressing myogenesis through the ubiquitination of myoblast determination protein 1
(MYOD) [116].
MURF-1 encodes a protein containing a RING finger domain, which is responsible for its
ubiquitin-ligase activity [112,117]. MURF-1 ubiquitinates and catalyses the degradation of contractile
proteins and thick filaments, such as myosin and troponin I, with the sparing of thin filaments such
as actin [118,119]. Besides a role in the UPS, increased FOXO activation also upregulates protein
degradation and clearance through the autophagy pathways [106]. In muscle, this appears to be
mediated through the direct upregulation of autophagy genes such as LC3, BNIP3 and ATG through
the FOXO pathway during muscular atrophy [120–122].
Postnatal myogenesis is an anabolic process important to the maintenance of muscle mass and
integrity. Insulin-like growth factor 1 (IGF-1) has been shown to be a positive driver of myogenesis,
whilst fibroblast growth factor (FGF), transforming growth factor β (TGF- β) and myostatin are
potent inhibitors [123–126]. In addition, various secreted WNT signalling factors positively influence
myogenesis. These are regulated by an array of stimuli, including exercise, nerve innervation and
dietary protein intake, and are mediated through various gene regulatory networks including the
T-box family, tbx6, ripply1 and mesp-ba in mesenchymal stem cell populations [127–129]. Ultimately,
this drives the expression of myogenic regulatory factors (MRFs) such as myogenic differentiation
1 (MYOD), myogenic factor 5 (MYF5) and myogenin (MYOG), this process being in mesenchymal
derived muscle progenitor cells called satellite cells [130–133]. Although some redundancy exists
in their cellular function, MYF5 is mostly implicated in mediating the proliferation of satellite cells
and MYOD in their differentiation into myoblasts, whilst downstream factors, including myogenin,
initiate further differentiation of mature myocytes followed by the fusion and formation of mature
myotubes [130–132] or mostly relevant for adult muscle, fusion with myofibers.
Below, we will describe how inflammation and glucocorticoids impact these regulatory processes
of muscle mass metabolism, driving a shift towards anti-anabolic and catabolic protein metabolism,
resulting in muscle wasting.
8. Effects of Inflammation of Muscle Metabolism
Inflammation is a well established driver of muscle wasting in preclinical models and strongly relates
to poor prognostic outcome and increased morbidity and mortality in patients with chronic inflammatory
diseases [134]. Pro-inflammatory cytokines such as TNFβα, IL-1β and IL-6, which are elevated in
chronic inflammation, are themselves reported to drive proteolysis and autophagy and suppress
myogenesis and protein synthesis in muscle [135–138]. Of these, TNF-α, at the apex of the inflammatory
cytokine cascade in many chronic inflammatory diseases, is critical in regulating inflammatory muscle
wasting. Here, its activation of the NF-kB and p-38 MAPK pathways directly induces muscle wasting
through the increased expression of the E3 ligases, atrogin-1 and MURF-1 and activation of the UPS
system [139–143]. In models of chronic inflammation, TNF-α also downregulates circulating levels of
IGF-1 and the downstream PI3K/AKT/mTOR signalling pathways, whilst upregulating the catabolic
FOXO pathway to suppress protein synthesis and myogenesis in muscle [141,142,144,145]. Another
factor implicated in inflammatory muscle wasting is myostatin. This is also reported to be increased in
chronic inflammation, where it positively correlates with markers of disease severity. Elevated myostatin
downregulates PI3K/AKT/mTOR signalling, promoting muscle atrophy [146,147]. Of interest, several
studies have reported elevated endogenous GC levels as being central mediators of inflammatory muscle
wasting. Here, the inflammatory activation of the hypothalamic/pituitary/adrenal (HPA) axis in response
results in an elevation of circulating cortisol to mediate muscle wasting [148–151]. Of note, the blockade of
endogenous GC production or muscle GR signalling could reverse muscle wasting in some experimental
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models [152,153]. This indicates that in addition to a direct impact of inflammation on intra-cellular
muscle mass regulatory processes, activation of the HPA axis as an evolutionarily conserved response
to suppress systemic inflammation can result in GC driven muscle wasting as an indirect effect of
inflammation on skeletal muscle.
9. Effects of Glucocorticoids on Muscle Metabolism
Extended exposure to therapeutic GCs results in the rapid onset of a GC induced muscle atrophy,
characterised by a decrease in myogenesis and protein synthesis and an increase in proteolysis and
atrophy of muscle fibres [9,154–157]. This leads to a significant decrease in muscle fibre size, with
a greater degree of wasting apparent in fast-twitch or type II muscle fibres [158]. The shift towards
greater catabolic loss of protein and decreased anabolic synthesis in muscle is elicited by GCs through
a number of pathways, including a decrease in IGF-1 signalling and an increase in negative regulators
of the mTOR pathways such as myostatin and the protein regulated in development and DNA
damage response 1 (REDD1) [157,159]. Similarly, as with inflammatory pathway activation, GCs
also activate the UPS and autophagy secondary to upregulation of the FOXO1 pathway [80,154,160].
In particular, the marked increase in degradation of contractile skeletal muscle proteins through the
UPS system is believed to be central in GC induced muscle wasting in vivo. This is supported by
several studies demonstrating the downregulation of the PI3K/AKT/mTOR signalling pathways and
the upregulation of the E3 ligases Atrogin-1 and MURF-1 in response to GCs [112]. Several studies have
also demonstrated a significant increase in 4E-BP1 and suppression of p70S6K in GC induced muscle
atrophy, demonstrating a role for reduced protein synthesis and regeneration [157,159]. Of interest, the
restoration of IGF-1 signalling can rescue GC induced myopathy in mice, demonstrating a crucial role
for this growth factor in the process of GC-induced myopathy [9,154–156]. Glucocorticoid mediated
muscle wasting has also been shown to be rescued through the in vivo deletion of myostatin, indicating
that the negative regulation of the IGF-1 pathway may also be a crucial step in this process [161–163].
10. Interaction between Inflammation and Glucocorticoids in Muscle
As with bone, many of the central inflammatory pathways that induce muscle wasting, including
the NF-kB and p38-MAPK pathways, are themselves suppressed by GC signalling, suggesting that
therapeutic application may protect against the process of inflammatory muscle wasting. However,
other elements of inflammatory muscle wasting such as the suppression of IGF-1 and induction of
myostatin and FOXO1 pathway activation are common components in both inflammatory and GC
induced muscle wasting (Figure 3). Understanding how these interact in vivo remains paramount in our
understanding of how therapeutic GCs should be applied in the setting of chronic inflammatory disease.
Some insights arise from clinical studies exploring these processes in patients with inflammatory
disease receiving GCs. Of note, in inflammatory myopathies arising directly from muscle inflammation,
such as with polymyositis and dermatomyositis, GCs are effective in controlling inflammation and
protecting against inflammatory muscle wasting and associated weakness [164]. Similarly, therapeutic
GCs are effective in preventing muscle wasting in patients with Duchenne muscular dystrophy (DMD),
where progressive muscle necrosis mediates loss of muscle [165–169]. However, in other inflammatory
diseases, where muscle wasting occurs secondarily to inflammation at a non-muscle site, the application
of therapeutic GCs is strongly associated with rapid loss of muscle mass [170,171]. These findings
may suggest that GCs can oppose the process of inflammatory muscle wasting when the active
inflammation is confined to the muscle, but promote muscle wasting when used to manage other
systemic chronic inflammatory diseases such as RA. As with GC induced osteoporosis in patients
with chronic inflammatory disease, the interpretation of these findings in relation to muscle wasting is
complicated by disease severity and duration and by concurrent DMARD therapies.
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GC induced muscle wasting and their interactions. Inflammatory cytokines such as TNF-α and IL-1
inhibit mammalian target of rapamycin (mTOR) signalling, dampening muscle protein synthesis, whilst
simultaneously inducing transcription of E3 ligases, leading to muscle proteolysis. Glucocorticoids
(GCs) inhibit inflammatory signalling, including nuclear factor kappa-light-chain-enhancer of activated
B cells (NF-κB) signalling, and therefore decrease inflammatory driven muscle wasting. Despite this,
GCs also drive muscle wasting th ough ever l pathways th mselves, including suppressio of the
IGF-1/AKT/mTOR signalling cascade, leading to decreas d protein synthesis and increa ed FOXO1
transcription. GR activation and dimerization in uce the transcription of myostatin (MSTN), FOXO1
and other E3 ligases, leading to increased proteolysis and diminished protein synthesis. Forkhead
box protein O1 (FOXO1), mammalian target of rapamycin (mTOR), insulin like growth factor (IGF-1),
(p-38-MAPK), glucocorticoid induced leucine zipper (GILZ), secretory leukocyte protease inhibitor
(SLPI), tristetraprolin (TTP), nuclear factor kappa-light-chain-enhancer of activated B cells (NF-κB),
glucocorticoid receptor (GR), myostatin (MSTN), and IGF-1 receptor (IGF-1 R).
11. Insights from Murine Models of Chronic Inflammation Receiving Therapeutic Glucocorticoids
Additi nal insight has come from murine models of polyarthritis receiving therapeutic GCs.
These are able to circumvent issues related to differences in disease activity between patients and
complications rising from th variou alternative anti-inflammatory drugs us d to manage disease in
patients. In one such tudy, we examined th role of the GC corticosterone, delivered s a monotherapy
in the TNF-tg murine model of polyarthritis, on net b ne and muscle metabolism [80]. This revealed
that therapeutic doses of GCs, whilst effective at suppressing disease activity, also potently suppressed
inflammatory osteoporosis and juxta articular bone loss. This confirmed that their capacity to suppress
inflammatory pathways that mediate inflammatory bone loss outweighed their deleterious effects
on bone metabolism. These bone sparing effects of GCs were mediated through the suppression of
pro-inflammatory osteoclasts’ activation, both systemically and at sites of inflammation. However,
whilst these treatments protected from inflammatory bone loss, we still observed a suppression of
anab lic bone formation i all mice receiving GCs, suggesting that long term administra ion may still
ultimately result in GIO.
Unlike bone, therapeutic GCs markedly exacerbated muscle wasting in mice with chronic inflammation.
This was characterized by a marked activation of the catabolic FOXO1 and UPS pathways [80]. Similar
findings had been reported in rats, where dexamethasone exacerbated inflammatory muscle wasting in
models of sepsis [172]. These data indicate that the beneficial effects of inflammatory suppression by GCs
in muscle were not sufficient to outweigh their deleterious actions on muscle metabolism. Whilst further
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work is required to better elucidate the actions of therapeutic GCs in the context of chronic inflammation,
these data shed light on the potential strengths and weaknesses of their application in muscle and bone. In
particular, they indicate that the management of side effects in muscle may need to be prioritised over
those in bone, in patients with chronic inflammatory diseases receiving therapeutic GCs.
12. Pre-Receptor Regulation of Therapeutic GC Action to Protect against Side Effects
The pre-receptor metabolism of GCs by the 11β-hydroxysteroid dehydrogenase (11β-HSD)
enzymes is recognised as a critical step in mediating GC signalling in many peripheral tissues. These
are the 11β-HSD type 1 (11β-HSD1) and type 2 (11β-HSD2). 11β-HSD1 is expressed in many tissues,
including the liver, bone, muscle and fat, where it converts inactive endogenous and therapeutic GCs
(such as corticosterone and prednisone) to their active counterparts (such as cortisol and prednisolone),
leading to a local accumulation and concentration of active GCs [173–175] (Figure 4). In contrast,
11β-HSD2 solely inactivates endogenous and therapeutic GCs within the kidney, providing circulating
inactive GC substrate for the peripheral 11β-HSD1 enzyme and supporting renal clearance of GCs [175].
Several key studies have demonstrated a critical role for the pre-receptor activation of GCs by 11β-HSD1
in mediating the deleterious actions of therapeutic GCs in muscle and bone [176,177]. Here, animals
with transgenic deletion of 11β-HSD1 are resistant to both exogenous GC induced muscle wasting and
osteoporosis. This raises the exciting possibility that therapeutic 11β-HSD1 inhibitors, widely explored
in the management of metabolic disease, may prevent bone loss and muscle wasting in patients
with chronic inflammatory diseases receiving GCs [178,179]. Further studies lend strength to this
concept, showing that 11β-HSD1 is potently upregulated within muscle cells and osteoblasts, where it
is potently upregulated by circulating inflammatory cytokines such as TNF-α and IL-1β [174,180,181].
Despite this, caution should be applied in this context, given that systemic deletion of 11β-HSD1 can
exacerbate disease activity in murine models of inflammation, secondary to a reduction in reactivation
of endogenous GC at sites of inflammation [182,183]. Consequently, further studies are required to
delineate the potential benefits and risks of 11β-HSD1 inhibition in chronic inflammatory disease.Int. J. Mol. Sci. 2019, 20, x FOR PEER REVIEW 12 of 22 
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13. Conclusions
Both chronic inflammation and therapeutic GCs are potent drivers for systemic bone and muscle
wasting resulting from an imbalance between anabolic and catabolic homeostasis. Whilst therapeutic
GCs oppose many of the inflammatory pathways that drive bone and muscle wasting, they share
common pathways that promote anti-anabolic and catabolic metabolism of bone and muscle and
can drive or exacerbate these deleterious processes in chronic inflammatory disease. However, these
relationships are invariably complicated by the nature of the inflammatory disease in which therapeutic
GCs are utilized. Intriguingly, 11β-HSD1 inhibitors may possess the potential to prevent the deleterious
actions of therapeutic GCs in the backdrop of chronic inflammation. However, further studies are
required to assess their efficacy and safety in this context.
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